查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
ELISpot 检测和 FluoroSpot 检测的全球市场：按产品、按应用、按最终用户 - 预测（截至 2028 年）
市场调查报告书
商品编码
1386910

ELISpot 检测和 FluoroSpot 检测的全球市场：按产品、按应用、按最终用户 - 预测（截至 2028 年）

ELISpot and FluoroSpot Assay Market by Product (Assay kit (Technique, Utility, Analyte (T Cell and B Cell assay)), Analyzer), Application (Transplants, Infectious Diseases, Vaccine Development, Cancer Research), End User - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 234 Pages | 订单完成后即时交付

价格
简介目录

报告概述

调查范围
调查年份 2020-2028
基准年 2023年
预测期 2023-2028
考虑单位 金额（百万美元）
部分 产品、应用、最终用户、地区
目标区域 北美、欧洲、亚太等地区

全球 ELISpot 检测/FluoroSpot 检测市场规模预计到 2023 年将达到 2.92 亿美元，到 2028 年将达到 4.21 亿美元，预测期内年复合成长率为 7.6%。

该市场是由 ELISpot 和 FluoroSpot 检测在肿瘤学中的使用增加以及生物技术和生物製药行业的成长等因素所推动的。另一方面，替代检测技术的出现预计将在未来年度在一定程度上限制市场成长。

“在预测期内，检测试剂盒将占据产品市场的最大市场占有率。”

2022 年，套件占据主要市场占有率。这是因为与ELISA等其他检测方法相比，该试剂盒具有特异性高、灵敏度高、检出限好的优点，并且广泛应用于研究和诊断领域。

“诊断应用领域占据了最大的市场占有率。”

诊断应用在 2022 年占据最大的市场占有率，但考虑到它们在疫苗开发、临床试验和癌症研究等研究应用中的使用，预计研究应用将从 2023 年到 2028 年增长最快。

“亚太地区的年复合成长率将最高。”

从 2022 年起，亚太地区可能会保持较大的市场占有率。亚太市场受到非传染性疾病 (NCD) 的增加、疫苗研究资金和不断变化的疾病概况的推动。另一方面，由于主要企业的存在以及先进技术 ELISpot 和 FluoroSpot 检测试剂盒和分析仪的可得性，预计北美在未来年度将显着成长。

“预计欧洲在预测期内将以第三高的年复合成长率增长。”

该市场的成长得益于欧洲优秀的研究和学术传统、包括自体自体免疫疾病和感染疾病在内的慢性病发病率的不断上升，以及许多欧洲国家政府对研究和医疗保健的资助。这是因为我们支持这一发展和技术的采用。

本报告研究和分析了全球 ELISpot 检测/FluoroSpot 检测市场，提供了包括关键驱动因素和抑制因素、竞争形势和未来趋势资讯。

目录

第1章简介

第2章调查方法

第3章执行摘要

第4章重要考察

  • ELISpot 检测/FluoroSpot 检测市场概述
  • ELISpot Assay/FluoroSpot Assay Kit 市场：依技术分类（2023-2028）
  • 北美 ELISpot 检测/FluoroSpot 检测市场：按产品、按国家/地区划分（2022 年）
  • ELISpot 检测/FluoroSpot 检测市场：地理成长机会

第5章市场概况

  • 介绍
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 价值链分析
  • 供应链分析
  • 技术分析
  • 波特五力分析
  • 主要利害关係人和采购标准
    • 采购过程中的主要利害关係人
    • 购买标准
  • 监管形势
    • 美国
    • 加拿大
    • 欧洲
    • 日本
    • 中国
    • 印度
    • 俄罗斯
    • 沙乌地阿拉伯
    • 墨西哥
    • 巴西
    • 韩国
    • 中东
    • 非洲
  • 重大会议及活动
  • 专利分析
  • 价格分析
  • 贸易分析
  • 生态系分析
  • 影响客户业务的趋势/干扰

第6章ELISpot 检测/FluoroSpot 检测市场：按产品

  • 介绍
  • 检测试剂盒
    • 检测试剂盒市场：依技术分类
    • 检测试剂盒市场：依应用分类
    • 检测试剂盒市场：依分析物分类
  • 分析仪
  • 辅助产品

第7章ELISpot Assay/FluoroSpot Assay 市场：按应用

  • 介绍
  • 诊断用途
    • 感染疾病
    • 移植
  • 用于研究和
    • 疫苗开发
    • 临床试验
    • 癌症研究

第8章ELISpot 侦测/FluoroSpot 侦测市场：依最终使用者分类

  • 介绍
  • 医院、临床研究所
  • 研究机构
  • 生物製药公司、委外研发机构

第9章ELISpot 检测/FluoroSpot 检测市场：按地区

  • 介绍
  • 北美洲
    • 北美经济衰退的影响
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲经济衰退的影响
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 亚太地区经济衰退的影响
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他地区

第10章竞争形势

  • 概述
  • 主要企业采取的策略
  • 市场占有率分析
  • 收益占有率分析
  • 公司评级矩阵
  • 中小企业/新创企业评估矩阵
  • 竞争基准化分析
  • 企业足迹
  • 竞争场景

第11章公司简介

  • 主要企业
    • OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.)
    • BECTON, DICKINSON AND COMPANY
    • BIO-TECHNE
    • CELLULAR TECHNOLOGY LIMITED
    • MABTECH
    • ABCAM PLC
    • MERCK KGAA
    • AUTOIMMUN DIAGNOSTIKA GMBH
    • U-CYTECH
    • MIKROGEN DIAGNOSTIK
    • MEDIX BIOCHEMICA
    • ABNOVA CORPORATION
    • ANOGEN-YES BIOTECH LABORATORIES LTD.
    • BIORBYT LTD.
    • BIOSYS SCIENTIFIC DEVICES GMBH
  • 其他公司
    • JACKSON IMMUNORESEARCH INC.
    • IST SCIENTIFIC
    • SERVA ELECTROPHORESIS GMBH
    • ACROBIOSYSTEMS
    • NATIONAL ANALYTICAL CORPORATION
    • STEMCELL TECHNOLOGIES
    • ZENBIO, INC.
    • BOC SCIENCES
    • TOKYO CHEMICAL INDUSTRY CO., LTD.
    • MP BIOMEDICALS

第12章附录

简介目录
Product Code: MD 6791

Report Description

Scope of the Report
Years Considered for the Study2020-2028
Base Year2023
Forecast Period2023-2028
Units ConsideredValue (USD) Million
SegmentsProduct, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, ROW

The global ELISpot and FluoroSpot Assays Market is expected to reach USD 421 million by 2028 from USD 292 million in 2023, at a CAGR of 7.6% during the forecast period. Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries. On the other hand, availability of alternative detection technologies is expected to limit market growth to a certain extent in the coming years.

"The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product' smarket, during the forecast period"

The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products. In 2022, kits accounted for a sizable market share because they offer advantages in terms of high specificity and sensitivity and better detection limits as compared to other assays such as ELISA as well as their wide applications in the field of research and diagnostics.

"Diagnostic application segment accounted for the largest market share"

Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application. The Diagnostic application segment accounted for the largest market share in 2022., while research application is expected to grow at the fastest rate in the years ahead, from 2023 to 2028 considering their practice in several research applications, such as vaccine development, clinical trials, and cancer research.

"APAC region accounted for the highest CAGR"

The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a significant market share in 2022 and the future. The Asia-Pacific market is being propelled by an increase in non-communicable (NCD), research funding on vaccines and changing disease profiles. North America, on the other hand, will experience significant growth in the coming years due to the presence of key players, the availability of technologically advanced ELISpot and FluoroSpot assay kits and analyzers.

"Europe is estimated to register the third highest CAGR during the forecast period."

In this report, the ELISpot and FluoroSpot Assays market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the third highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of chronic diseases, including autoimmune disorders and infectious diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%

Lits of Companies Profiled in the Report:

  • Oxford Immunotec USA, Inc. (Subsidiary of Revvity Inc.) (UK)
  • Becton, Dickinson and Company (BD) (US)
  • Cellular Technology Limited (CTL) (US)
  • Mabtech (Sweden)
  • Abcam plc. (UK)
  • Bio-Techne (US)
  • Merck KGaA (Germany)
  • Autoimmun Diagnostika GmbH (Germany)
  • U-CyTech (Netherland)
  • Mikrogen Diagnostik (Germany)
  • Medix Biochemica (Finland)
  • Abnova Corporation (Taiwan)
  • Anogen-Yes Biotech Laboratories Ltd. (Canada)
  • Biorbyt Ltd (UK)
  • BIOSYS Scientific Devices GmbH (Germany)
  • Jackson ImmunoResearch Inc. (US)
  • iST Scientific (UK)
  • SERVA Electrophoresis GmbH (Germany)
  • ACROBiosystems (US)
  • NATIONAL ANALYTICAL CORPORATION (India)
  • STEMCELL Technologies. (Canada)
  • ZenBio, Inc (US)
  • BOC Sciences (US)
  • Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)
  • MP Biomedicals (California)

Research Coverage:

This report studies the ELISpot and FluoroSpot Assays market based on product, applications, End user, and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total ELISpot and FluoroSpot Assays market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.

Market Penetration: Comprehensive information on ELISpot and FluoroSpot assay products offered by the top 25 players in the market. The report analyses the ELISpot and FluoroSpot Assays market by product, application, end user and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot Assays market

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the ELISpot and FluoroSpot Assays market

Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 REGIONAL SEGMENTATION
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 MARKET STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
  • 1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.) (UK)
    • FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • 2.2.1 GROWTH FORECAST
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 8 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT
  • 2.7 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 10 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 ELISPOT AND FLUOROSPOT ASSAYS MARKET OVERVIEW
    • FIGURE 14 RISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • 4.2 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2023-2028
    • FIGURE 15 ELISPOT ASSAY KITS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • 4.3 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT AND COUNTRY (2022)
    • FIGURE 16 ASSAY KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ELISPOT AND FLUOROSPOT ASSAYS MARKET IN 2022
  • 4.4 ELISPOT AND FLUOROSPOT ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
    • FIGURE 19 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
    • TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
      • 5.2.1.2 Increasing vaccine development to address challenges of antimicrobial resistance
      • 5.2.1.3 Increasing use of ELISpot and FluoroSpot assays in oncology
    • TABLE 3 INCIDENCE OF CANCER IN MEN, 2020
    • TABLE 4 INCIDENCE OF CANCER IN WOMEN, 2020
      • 5.2.1.4 ELISpot assays as diagnostic tool in drug hypersensitivity reaction
    • TABLE 5 EXAMPLES OF ELISPOT ASSAYS IN DRUG HYPERSENSITIVITY REACTIONS
      • 5.2.1.5 Growth in biotechnology and biopharmaceutical industries
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables
      • 5.2.2.2 High cost of assay kits and analyzers
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Use of FluoroSpot assays for multiple-analyte detection in single well
      • 5.2.3.2 Emerging economies
    • FIGURE 20 HEALTHCARE EXPENDITURE PER CAPITA IN BRIC COUNTRIES, 2012-2020
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Availability of alternative detection technologies
      • 5.2.4.2 Dearth of skilled professionals
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 22 DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 BARGAINING POWER OF SUPPLIERS
    • 5.6.5 THREAT OF SUBSTITUTES
  • 5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
    • TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
    • 5.7.2 BUYING CRITERIA
    • FIGURE 24 KEY BUYING CRITERIA FOR END USERS
    • TABLE 7 KEY BUYING CRITERIA FOR END USERS
  • 5.8 REGULATORY LANDSCAPE
    • TABLE 8 REGULATORY AUTHORITIES GOVERNING ELISPOT AND FLUOROSPOT ASSAYS MARKET
    • 5.8.1 US
    • TABLE 9 US: CLASSIFICATION OF ELISPOT AND FLUOROSPOT ASSAY PRODUCTS
    • FIGURE 25 US: REGULATORY PROCESS FOR IVD DEVICES
    • 5.8.2 CANADA
    • FIGURE 26 CANADA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.8.3 EUROPE
    • TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
    • 5.8.4 JAPAN
    • FIGURE 27 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.8.5 CHINA
    • TABLE 12 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.8.6 INDIA
    • FIGURE 28 INDIA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.8.7 RUSSIA
    • TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES
    • 5.8.8 SAUDI ARABIA
    • TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.8.9 MEXICO
    • FIGURE 29 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.8.10 BRAZIL
    • FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    • 5.8.11 SOUTH KOREA
    • TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.8.12 MIDDLE EAST
    • 5.8.13 AFRICA
  • 5.9 KEY CONFERENCES AND EVENTS
    • TABLE 17 LIST OF CONFERENCES AND EVENTS, 2023-2025
  • 5.10 PATENT ANALYSIS
    • FIGURE 31 PATENT ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS
  • 5.11 PRICING ANALYSIS
    • TABLE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: PRICE RANGE FOR ELISPOT AND FLUOROSPOT ASSAY PRODUCTS
    • TABLE 19 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
  • 5.12 TRADE ANALYSIS
    • 5.12.1 TRADE ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS
    • TABLE 20 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017-2022 (USD MILLION)
    • TABLE 21 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017-2022 (USD MILLION)
  • 5.13 ECOSYSTEM ANALYSIS
    • 5.13.1 ROLE IN ECOSYSTEM
    • FIGURE 32 KEY PLAYERS OPERATING IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

6 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 22 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
  • 6.2 ASSAY KITS
    • TABLE 23 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 24 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 25 EUROPE: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 26 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • 6.2.1 ASSAY KITS MARKET, BY TECHNIQUE
    • TABLE 27 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2020-2028 (USD MILLION)
      • 6.2.1.1 ELISpot assay kits
        • 6.2.1.1.1 Need for highly sensitive immune monitoring requirements in clinical trials to drive market
    • TABLE 28 ELISPOT ASSAY KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 29 NORTH AMERICA: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 30 EUROPE: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
      • 6.2.1.2 FluoroSpot assay kits
        • 6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancements to support market growth
    • TABLE 32 FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 33 NORTH AMERICA: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 34 EUROPE: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • 6.2.2 ASSAY KITS MARKET, BY UTILITY
    • TABLE 36 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY, 2020-2028 (USD MILLION)
      • 6.2.2.1 Diagnostic kits
        • 6.2.2.1.1 Need for early diagnosis of infections to drive market
    • TABLE 37 CANCER CASES, BY TYPE, 2020
    • TABLE 38 DIAGNOSTIC KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 40 EUROPE: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
      • 6.2.2.2 Research kits
        • 6.2.2.2.1 Increasing investments in vaccine research, clinical trials, and cancer research to drive market
    • TABLE 42 RESEARCH KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 43 NORTH AMERICA: RESEARCH KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 44 EUROPE: RESEARCH KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: RESEARCH KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • 6.2.3 ASSAY KITS MARKET, BY ANALYTE
    • TABLE 46 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY ANALYTE, 2020-2028 (USD MILLION)
      • 6.2.3.1 T-cell-based kits
        • 6.2.3.1.1 Low concentrations of infection-released analytes necessitate use of T-cell-based kits
    • TABLE 47 T-CELL-BASED KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 48 NORTH AMERICA: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 49 EUROPE: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 50 ASIA PACIFIC: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
      • 6.2.3.2 B-cell-based kits
        • 6.2.3.2.1 Detection of B-cell-based antibodies useful to study cell response post-infection/vaccination
    • TABLE 51 B-CELL-BASED KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 52 NORTH AMERICA: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 53 EUROPE: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 54 ASIA PACIFIC: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
      • 6.2.3.3 Other analyte kits
    • TABLE 55 OTHER ANALYTE KITS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 57 EUROPE: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
  • 6.3 ANALYZERS
    • 6.3.1 ADOPTION OF ASSAY KITS TO DRIVE USE OF ANALYZERS
    • TABLE 59 ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 61 EUROPE: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
  • 6.4 ANCILLARY PRODUCTS
    • 6.4.1 REPEATED USAGE OF ANCILLARY PRODUCTS INTEGRAL TO RELIABILITY AND SUCCESS OF ELISPOT AND FLUOROSPOT ASSAYS
    • TABLE 63 ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 64 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 65 EUROPE: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)

7 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 67 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
  • 7.2 DIAGNOSTIC APPLICATIONS
    • TABLE 68 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 69 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 71 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)
    • 7.2.1 INFECTIOUS DISEASES
      • 7.2.1.1 Rising prevalence of infectious diseases to drive market
    • TABLE 73 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 74 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 75 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2028 (USD MILLION)
    • 7.2.2 TRANSPLANTS
      • 7.2.2.1 Growing incidence of infections caused during transplant procedures to drive demand
    • FIGURE 33 PATIENTS ON WAITING LIST FOR ORGAN TRANSPLANTS, 2023
    • FIGURE 34 NUMBER OF TRANSPLANTS PERFORMED IN 2023
    • TABLE 77 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 78 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 79 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020-2028 (USD MILLION)
  • 7.3 RESEARCH APPLICATIONS
    • TABLE 81 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2028 (USD MILLION)
    • TABLE 82 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 84 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 85 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020-2028 (USD MILLION)
    • 7.3.1 VACCINE DEVELOPMENT
      • 7.3.1.1 Largest and fastest-growing segment of market
    • TABLE 86 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 87 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 88 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 89 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020-2028 (USD MILLION)
    • 7.3.2 CLINICAL TRIALS
      • 7.3.2.1 Growing number of clinical trials to drive demand
    • FIGURE 35 NUMBER OF CLINICAL TRIALS, BY REGION, 2010-2021
    • FIGURE 36 NUMBER OF REGISTERED CLINICAL STUDIES, 2023
    • TABLE 90 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 91 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 92 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020-2028 (USD MILLION)
    • 7.3.3 CANCER RESEARCH
      • 7.3.3.1 Rising prevalence of cancer to support market growth
    • TABLE 94 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 95 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 96 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020-2028 (USD MILLION)

8 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 98 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
  • 8.2 HOSPITAL AND CLINICAL LABORATORIES
    • 8.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING COUNTRIES TO DRIVE MARKET
    • TABLE 99 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 100 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 101 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020-2028 (USD MILLION)
  • 8.3 RESEARCH INSTITUTES
    • 8.3.1 FASTEST-GROWING END USER OF ELISPOT AND FLUOROSPOT ASSAYS
    • TABLE 103 GRANTS, BY CANCER TYPE, 2023
    • TABLE 104 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 105 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 106 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 107 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020-2028 (USD MILLION)
  • 8.4 BIOPHARMACEUTICAL COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
    • 8.4.1 GROWTH IN BIOTECHNOLOGY INDUSTRY TO PROPEL GROWTH
    • TABLE 108 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2020-2028 (USD MILLION)
    • TABLE 109 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 110 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020-2028 (USD MILLION)

9 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 112 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2020-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 37 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT
    • TABLE 113 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 114 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 115 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 116 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.2.1 NORTH AMERICA: RECESSION IMPACT
    • 9.2.2 US
      • 9.2.2.1 Rising prevalence of chronic diseases to drive market
    • TABLE 117 US: KEY MACROINDICATORS
    • TABLE 118 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 119 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 120 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.2.3 CANADA
      • 9.2.3.1 Rising healthcare expenditure to drive adoption of ELISpot and FluoroSpot assays
    • TABLE 121 CANADA: KEY MACROINDICATORS
    • TABLE 122 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 123 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 124 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 125 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY
    • 9.3.1 EUROPE: RECESSION IMPACT
    • TABLE 126 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 127 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 128 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 129 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.3.2 GERMANY
      • 9.3.2.1 Fastest-growing country in European ELISpot and FluoroSpot assays market
    • TABLE 130 GERMANY: KEY MACROINDICATORS
    • TABLE 131 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 132 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 133 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.3.3 UK
      • 9.3.3.1 Rising prevalence of NCDs to drive market
    • TABLE 134 UK: KEY MACROINDICATORS
    • TABLE 135 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 136 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 137 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.3.4 FRANCE
      • 9.3.4.1 Need for early disease diagnosis to support market growth
    • TABLE 138 FRANCE: KEY MACROINDICATORS
    • TABLE 139 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 140 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 141 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.3.5 ITALY
      • 9.3.5.1 Increasing incidence of cancer to propel market
    • TABLE 142 ITALY: KEY MACROINDICATORS
    • TABLE 143 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 144 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 145 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.3.6 SPAIN
      • 9.3.6.1 High incidence of chronic diseases to drive market
    • TABLE 146 SPAIN: KEY MACROINDICATORS
    • TABLE 147 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 148 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 149 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.3.7 REST OF EUROPE
    • TABLE 150 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 151 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 152 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • 9.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 38 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT
    • TABLE 153 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)
    • TABLE 154 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 156 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.4.2 CHINA
      • 9.4.2.1 Rising focus on vaccine development and cancer research to drive market
    • TABLE 157 CHINA: KEY MACROINDICATORS
    • TABLE 158 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 159 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 160 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.4.3 JAPAN
      • 9.4.3.1 Increased focus on vaccine research to support market growth
    • TABLE 161 JAPAN: KEY MACROINDICATORS
    • TABLE 162 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 163 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 164 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.4.4 INDIA
      • 9.4.4.1 Increasing focus on cancer research and therapy to drive market
    • TABLE 165 INDIA: KEY MACROINDICATORS
    • TABLE 166 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 167 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 168 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
    • 9.4.5 REST OF ASIA PACIFIC
    • TABLE 169 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 170 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 171 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)
  • 9.5 REST OF THE WORLD
    • TABLE 172 REST OF THE WORLD: POPULATION AGED 65 AND ABOVE, 2022
    • 9.5.1 REST OF THE WORLD: RECESSION IMPACT
    • TABLE 173 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2028 (USD MILLION)
    • TABLE 174 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)
    • TABLE 175 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2028 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 176 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
  • 10.3 MARKET SHARE ANALYSIS
    • TABLE 177 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DEGREE OF COMPETITION
  • 10.4 REVENUE SHARE ANALYSIS
    • FIGURE 39 REVENUE ANALYSIS OF KEY PUBLIC PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
    • FIGURE 40 ELISPOT AND FLUOROSPOT ASSAYS: MARKET RANKING ANALYSIS, 2022
  • 10.5 COMPANY EVALUATION MATRIX
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • FIGURE 41 ELISPOT AND FLUOROSPOT ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2022
  • 10.6 SME/STARTUP EVALUATION MATRIX
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 RESPONSIVE COMPANIES
    • 10.6.3 DYNAMIC COMPANIES
    • 10.6.4 STARTING BLOCKS
    • FIGURE 42 ELISPOT AND FLUOROSPOT ASSAYS MARKET: SME/STARTUP EVALUATION MATRIX, 2022
  • 10.7 COMPETITIVE BENCHMARKING
    • TABLE 178 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • 10.8 COMPANY FOOTPRINT
    • TABLE 179 COMPANY FOOTPRINT
    • TABLE 180 PRODUCT FOOTPRINT
    • TABLE 181 REGIONAL FOOTPRINT
  • 10.9 COMPETITIVE SCENARIO
    • 10.9.1 PRODUCT LAUNCHES
    • TABLE 182 KEY PRODUCT LAUNCHES, JANUARY 2020-OCTOBER 2023
    • 10.9.2 DEALS
    • TABLE 183 KEY DEALS, JANUARY 2020-OCTOBER 2023
    • 10.9.3 OTHER DEVELOPMENTS
    • TABLE 184 OTHER KEY DEVELOPMENTS, JANUARY 2020-OCTOBER 2023

11 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
  • 11.1 KEY PLAYERS
    • 11.1.1 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.)
    • TABLE 185 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.): BUSINESS OVERVIEW
    • FIGURE 43 REVVITY, INC.: COMPANY SNAPSHOT (2023)
    • 11.1.2 BECTON, DICKINSON AND COMPANY
    • TABLE 186 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 11.1.3 BIO-TECHNE
    • TABLE 187 BIO-TECHNE: BUSINESS OVERVIEW
    • FIGURE 45 BIO-TECHNE: COMPANY SNAPSHOT (2023)
    • 11.1.4 CELLULAR TECHNOLOGY LIMITED
    • TABLE 188 CELLULAR TECHNOLOGY LIMITED: BUSINESS OVERVIEW
    • 11.1.5 MABTECH
    • TABLE 189 MABTECH: BUSINESS OVERVIEW
    • 11.1.6 ABCAM PLC
    • TABLE 190 ABCAM PLC: BUSINESS OVERVIEW
    • FIGURE 46 ABCAM PLC: COMPANY SNAPSHOT (2022)
    • 11.1.7 MERCK KGAA
    • TABLE 191 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 11.1.8 AUTOIMMUN DIAGNOSTIKA GMBH
    • TABLE 192 AUTOIMMUN DIAGNOSTIKA GMBH: BUSINESS OVERVIEW
    • 11.1.9 U-CYTECH
    • TABLE 193 U-CYTECH: BUSINESS OVERVIEW
    • 11.1.10 MIKROGEN DIAGNOSTIK
    • TABLE 194 MIKROGEN DIAGNOSTIK: BUSINESS OVERVIEW
    • 11.1.11 MEDIX BIOCHEMICA
    • TABLE 195 MEDIX BIOCHEMICA: BUSINESS OVERVIEW
    • 11.1.12 ABNOVA CORPORATION
    • TABLE 196 ABNOVA CORPORATION: BUSINESS OVERVIEW
    • 11.1.13 ANOGEN-YES BIOTECH LABORATORIES LTD.
    • TABLE 197 ANOGEN-YES BIOTECH LABORATORIES LTD.: BUSINESS OVERVIEW
    • 11.1.14 BIORBYT LTD.
    • TABLE 198 BIORBYT LTD.: BUSINESS OVERVIEW
    • 11.1.15 BIOSYS SCIENTIFIC DEVICES GMBH
    • TABLE 199 BIOSYS SCIENTIFIC DEVICES GMBH: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 JACKSON IMMUNORESEARCH INC.
    • TABLE 200 JACKSON IMMUNORESEARCH INC.: BUSINESS OVERVIEW
    • 11.2.2 IST SCIENTIFIC
    • TABLE 201 IST SCIENTIFIC: BUSINESS OVERVIEW
    • 11.2.3 SERVA ELECTROPHORESIS GMBH
    • TABLE 202 SERVA ELECTROPHORESIS GMBH: BUSINESS OVERVIEW
    • 11.2.4 ACROBIOSYSTEMS
    • TABLE 203 ACROBIOSYSTEMS: BUSINESS OVERVIEW
    • 11.2.5 NATIONAL ANALYTICAL CORPORATION
    • TABLE 204 NATIONAL ANALYTICAL CORPORATION: BUSINESS OVERVIEW
    • 11.2.6 STEMCELL TECHNOLOGIES
    • TABLE 205 STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW
    • 11.2.7 ZENBIO, INC.
    • TABLE 206 ZENBIO, INC.: BUSINESS OVERVIEW
    • 11.2.8 BOC SCIENCES
    • TABLE 207 BOC SCIENCES: BUSINESS OVERVIEW
    • 11.2.9 TOKYO CHEMICAL INDUSTRY CO., LTD.
    • TABLE 208 TOKYO CHEMICAL INDUSTRY CO., LTD.: BUSINESS OVERVIEW
    • 11.2.10 MP BIOMEDICALS
    • TABLE 209 MP BIOMEDICALS: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2 DISCUSSION GUIDE
  • 12.3 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4 CUSTOMIZATION OPTIONS
  • 12.5 RELATED REPORTS
  • 12.6 AUTHOR DETAILS